Abstract
Purpose: :
To evaluate the efficacy and safety of intravitreal injection of triamcinolone acetonide (TA) for the treatment of macular edema due to central retinal vein occlusion (CRVO).
Methods: :
Twenty patients (20 eyes) with macular edema due to CRVO who had visual acuity (VA) less than 20/50 were enrolled. TA (4 mg) was injected into the vitreous cavity and the patients were followed for 6 months. The best–corrected visual acuity (BCVA), intraocular pressure (IOP), and complications were assessed at baseline and 1, 3, and 6 months after intravitreal TA injection.
Results: :
The mean logMAR VA was 1.01±0.45 at baseline and improved significantly to 0.69±0.52 at 1 month (p<0.01) , 0.68±0.46 at 3 months (p<0.01) , and 0.78±0.46 at 6 months (p<0.01). At 6 months, the BCVA improved by 3 or more lines in 11 eyes (55%) and deteriorated by 3 or more lines in 1 eye (5%). The IOP levels increased to 22 mmHg or higher in 9 eyes (45%); however, they were well controlled by medications. Retinal detachment developed in one eye (5%) 9 months postoperatively.
Conclusions: :
: Injection of TA for the treatment of macular edema due to CRVO seems to improve the BCVA for at least the first 6 months postoperatively after injection.
Keywords: vascular occlusion/vascular occlusive disease • macula/fovea • injection